Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who are receiving a type of heart-lung bypass support called V-A ECMO (a machine that helps pump blood when the heart is too weak) due to severe heart failure affecting the left side or both sides of the heart
- People who started V-A ECMO support no more than 16 hours before entering the trial
- People who are receiving a heart-stimulating medication called dobutamine at a dose of at least 2 mcg/kg/min
- People whose norepinephrine (a blood pressure medication) dose is no higher than 0.4 mcg/kg/min
- People whose heart rate is 80 beats per minute or more, with a heart rhythm that is either normal, atrial fibrillation, or atrial flutter, after V-A ECMO was started
Who may not be able to join:
- People who object during the deferred consent process (confirm with trial site)
- People who only used V-A ECMO during a surgical or other procedure, where the machine was removed before the procedure ended
- People who have a permanent implanted heart pump device called an LVAD
- People who have a specific type of dangerous irregular heartbeat (polymorphic ventricular tachycardia) that requires beta-blocker treatment
- People whose heart failure affects only the right side of the heart (for example, caused by a pulmonary embolism)
- People who require high doses of dobutamine above 6.0 mcg/kg/min
- People who are receiving a medication called epinephrine by infusion
- People showing signs that not enough blood is flowing through the heart, such as: the heart's aortic valve not opening, very low pulse pressure readings (below 10 mmHg, with an intra-aortic balloon pump on standby), or a specific finding on heart ultrasound called spontaneous contrast
- People who have a known contraindication, intolerance, or allergy to a medication called esmolol
- People with a specific type of heart conduction problem known as second- or third-degree AV block
- People who are pregnant
- People whose life expectancy is less than 24 hours
- People already participating in another randomised clinical trial (for example, the On Scene trial or the Left Ventricular Unloading trial)
- People for whom the study treatment cannot be started within 4 hours of being enrolled in the trial
- People who have previously had a heart transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christiaan L. Meuwese, Erasmus Medical Center
Phone: 0631135752
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change (delta) in heart rate 24 hours after randomization.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.